Drug Development

Articles

The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.

Lilly and CureVac Partner on mRNA Cancer Vaccines in $1.8-Billion Deal

CordenPharma will expand development capacity for small molecules, peptides, and carbohydrates at its Liestal, Switzerland site

CordenPharma Invests in Small Molecule API Development Capacity

Stelara (ustekinumab), already approved for treating adults, is now also approved for treating adolescents with moderate to severe plaque psoriasis.

FDA Expands Approval for J&J’s Psoriasis Biologic

The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.

GSK’s Shingles Vaccine Approved in Canada

The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.

Batavia Biosciences Expands Viral Vector Facilities

Dow’s portfolio of solutions for pharmaceutical applications now includes products from Dow Corning’s silicone technology platform. 

Dow Highlights Solutions for Formulation Challenges at CPhI Worldwide

Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity. 

FDA Licenses Second Samsung BioLogics Facility

The committee has voted unanimously to approve Spark Therapeutics’ gene therapy candidate, Luxturna (voretigene neparvovec), for treating a genetically inherited blindness.

FDA Committee Recommends Approval of Spark’s Eye-Disease Gene Therapy

The companies have entered into a strategic collaboration to establish a new cell therapy and regenerative medicine manufacturing platform, which includes a new manufacturing facility in Belgium.

Promethera and Shibuya Partner on New Cell-Therapy Manufacturing Platform

BARDA has entered a $12-million contract with biopharmaceutical firm Achaogen for the late-stage development of an antibiotic against resistant bacteria, and as a potential treatment for biowarfare agents.

APIs and Excipients